Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SOT101 |
Synonyms | |
Therapy Description |
SOT101 (SO-C101) is a fusion protein comprising IL15 and IL15RA, which may stimulate anti-tumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2502). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SOT101 | RL-I15|RLI 15|RLI-15|RLI15|SO C101|SOC101|SOT 101|SOT-101|SO-C101 | SOT101 (SO-C101) is a fusion protein comprising IL15 and IL15RA, which may stimulate anti-tumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2502). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04234113 | Phase I | SOT101 Pembrolizumab + SOT101 | Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors | Active, not recruiting | USA | FRA | ESP | CZE | 0 |